Analgesic nephropathy

New England Journal of Medicine

Volumn 338, Issue 7, 1998, Pages 446-452

  De Broe, Marc E ^a,b   Elseviers, Monique M ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; PHENACETIN;

ANALGESIC NEPHROPATHY; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DISEASE COURSE; HISTOPATHOLOGY; HUMAN; INTERSTITIAL NEPHRITIS; PRIORITY JOURNAL; REVIEW; SYMPTOMATOLOGY;

ANALGESICS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHRONIC DISEASE; DISEASE PROGRESSION; DRUG COMBINATIONS; HUMANS; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; KIDNEY PAPILLARY NECROSIS; PHENACETIN; SUBSTANCE-RELATED DISORDERS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0032509994     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199802123380707     Document Type: Review

References (39)

1. Henrich WL, Agodoa LE, Barrett B, et al. Analgesics and the kidney: summary and recommendations to the Scientific Advisory Board of the National Kidney Foundation from an ad hoc committee of the National Kidney Foundation. Am J Kidney Dis 1996;27:162-5.
2. De Broe ME, Elseviers MM, Bengtsson U, et al. Analgesic ncphropathy. Nephrol Dial Transplant 1996;11:2407-8.
3. Duggin GG. Combination analgesic-induced kidney disease: the Australian experience. Am J Kidney Dis 1996;28:Suppl 1:S39-S47.
4. Kincaid-Smith P, Nanra RS. Lithium-induced and analgesic-induced renal diseases. In: Schrier RW, Gottschalk CW, eds. Diseases of the kidney. 5th ed. Vol. 2. Boston: Little, Brown, 1993:1099-129.
5. Elseviers MM, Bosteels V, Cambier P, et al. Diagnostic criteria of analgesic nephropathy in patients with end-stage renal failure: results of the Belgian study. Nephrol Dial Transplant 1992;7:479-86.
6. Elseviers MM, Waller I, Nenoy D, et al. Evaluation of diagnostic criteria for analgesic nephropathy in patients with end-stage renal failure: results of the ANNE study. Nephrol Dial Transplant 1995;10:808-14.
7. Elseviers MM, De Schepper A, Corthouts R, et al. High diagnostic performance of CT scan for analgesic nephropathy in patients with incipient to severe renal failure. Kidney Int 1995;48:1316-23.
8. Prescott LF. Analgesic nephropathy: a reassessment of the role of phenacetin and other analgesics. Drugs 1982;23:75-149.
9. Nanra RS, Kincaid-Smith P. Chronic effect of analgesics on the kidney. Prog Biochem Pharmacol 1972;7:285-323.
10. Raaflaub J, Dubach UC. Dose-dependent change in the pattern of phenacetin metabolism in man and its possible significance in analgesic nephropathy. Klin Wochenschr 1969;23:1286-7.
11. Bluemle LW Jr, Goldberg M. Renal accumulation of salicylate and phenacetin: possible mechanisms in the nephropathy of analgesic abuse. J Clin Invest 1969;47:2507-14.
12. Brunner FP, Selwood NH. End-stage renal failure due to analgesic nephropathy, its changing pattern and cardiovascular mortality. Nephrol Dial Transplant 1994;9:1371-6.
13. Stewart JH. The analgesic syndrome. In: Stewart JH, ed. Analgesic and NSAID-induced kidney disease. Oxford, England: Oxford University Press, 1993:58-66.
14. Noels LM, Elseviers MM, de Broe ME. Impact of legislative measures on the sales of analgesics and the subsequent prevalence of analgesic nephropathy: a comparative study in France, Sweden and Belgium. Nephrol Dial Transplant 1995;10:167-74.
15. Elseviers MM, De Broe ME. Combination analgesic involvement in the pathogenesis of analgesic nephropathy: the European perspective. Am J Kidney Dis 1996;28:Suppl 1:S48-S55.
16. Nanra RS. Analgesic nephropathy in the 1990s - an Australian perspective. Kidney Int Suppl 1993;42:S86-S92.
17. Nanra RS, Stuart-Taylor J, de Leon AH, White KH. Analgesic nephropathy: etjology, clinical syndrome, and clinicopathoiogic correlations in Australia. Kidney Int 1978;13:79-92.
18. Elseviers MM, De Broe ME. The ghost of phenacetin reappearing? Nephrol Dial Transplant 1994;9:1840-1.
19. McCredie M, Ford JM, Taylor JS, Stewart JH. Analgesics and cancer of the renal pelvis in New South Wales. Cancer 1982;49:2617-25.
20. Murray TG, Stolley PD, Anthony JC, Schinnar R, Hepler-Smith E, Jeffreys JL. Epidemiologie study of regular analgesic use and end-stage renal disease. Arch Intern Med 1983;143:1687-93.
21. Sandler DP, Smith JC, Weinberg CR, et al. Analgesic use and chronic renal disease. N Engl J Med 1989;320:1238-43.
22. Pommer W, Bronder E, Greiser E, et al. Regular analgesic intake and the risk of end-stage renal failure. Am J Nephrol 1989;9:403-12.
23. Morlans M, Laporte JR, Vidai X, Cabeza D, Stolley PD. End-stage renal disease and nonnarcotic analgesics: a case-control study. Br J Clin Pharmacol 1990;30:717-23.
24. Perneger TV, Whelton PK, Klag MJ. Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs. N Engl J Med 1994;331:1675-9.
25. Dubach UC, Rosner B, Pfister E. Epidemiologic study of abuse of analgesics containing phenacetin: renal morbidity and mortality (1968-1979). N Engl J Med 1983;308:357-62.
26. Elseviers MM, De Broe ME. A long-term prospective controlled study of analgesic abuse in Belgium. Kidney Int 1995;48:1912-9.
27. Murray RM. Genesis of analgesic nephropathy in the United Kingdom. Kidney Int 1978;13:50-7.
28. Barrett BJ. Acetaminophen and adverse chronic renal outcomes: an appraisal of the epidemiologic evidence. Am J Kidney Dis 1996;28:Suppl 1: S14-S19.
29. Spühler O, Zollinger HU. Die Chronisch-Interstitiëlle Nephritis. Z Klin Med 1953;151:1-50.
30. Perneger TV, Whelton PK, Klag MJ. Kidney failure and analgesic drugs. N Engl J Med 1995;332:1515-6.
31. Delzell E, Shapiro S. Commentary on the National Kidney Foundation position paper on analgesics and the kidney. Am J Kidney Dis 1996; 28:783-5.
32. Beard K, Perera DR, Jick H. Drug-induced parenchymal renal disease in outpatients. J Clin Pharmacol 1988;28:431-5.
33. Gurwitz JH, Avorn J, Ross-Degnan D, Lipsitz LA. Nonsteroidal anti-inflammatory drug-associated azotemia in the very old. JAMA 1990;264: 471-5.
34. Bennett WM, Henrich WL, Stoff JS. The renal effects of nonsteroidal anti-inflammatory drugs: summary and recommendations. Am J Kidney Dis 1996;28:Suppl 1:S56-S62.
35. Murray MD, Brater DC. Renal toxicity of the nonsteroidal anti-inflammatory drugs. Annu Rev Pharmacol Toxicol 1993;33:435-65.
36. Sandler DP, Burr FR, Weinberg CR. Nonsteroidal anti-inflammatory drugs and the risk for chronic renal disease. Ann Intern Med 1991;115: 165-72.
37. Nuyts GD, Van Vlem E, Thys J, et al. New occupational risk factors for chronic renal failure. Lancet 1995;346:7-11.
38. Zambraski EJ. The effects of nonsteroidal anti-inflammatory drugs on renal function: experimental studies in animals. Semin Nephrol 1995;15: 205-13.
39. Segasothy M, Samad SA, Zulfigar A, Bennett WM. Chronic renal disease and papillary necrosis associated with the long-term use of nonsteroidal anti-inflammatory drugs as the sole or predominant analgesic. Am J Kidney Dis 1994;24:17-24.